Sigyn Therapeutics Announces $5M Stock Repurchase Program
Ticker: SIGY · Form: 8-K · Filed: Jun 6, 2024 · CIK: 1642159
| Field | Detail |
|---|---|
| Company | Sigyn Therapeutics, Inc. (SIGY) |
| Form Type | 8-K |
| Filed Date | Jun 6, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $226,903, $6.00 |
| Sentiment | bullish |
Sentiment: bullish
Topics: stock-repurchase, shareholder-value
TL;DR
Sigyn is buying back up to $5M of its stock over the next year.
AI Summary
Sigyn Therapeutics, Inc. announced on June 6, 2024, that its Board of Directors approved a stock repurchase program. The company may repurchase up to $5.0 million of its common stock through June 6, 2025. This program reflects management's confidence in the company's value and its commitment to enhancing shareholder value.
Why It Matters
A stock repurchase program can signal management's belief that the company's stock is undervalued, potentially boosting investor confidence and share price.
Risk Assessment
Risk Level: medium — Stock repurchase programs can be positive, but the actual impact depends on the company's financial health and the market conditions.
Key Numbers
- $5.0M — Stock Repurchase Authorization (Maximum amount the company can spend on repurchasing its own stock.)
Key Players & Entities
- Sigyn Therapeutics, Inc. (company) — The company making the announcement.
- $5.0 million (dollar_amount) — The maximum amount authorized for stock repurchase.
- June 6, 2025 (date) — The expiration date of the stock repurchase program.
- June 6, 2024 (date) — The date the Board of Directors approved the program.
FAQ
What is the total amount authorized for the stock repurchase program?
The Board of Directors authorized the repurchase of up to $5.0 million of the company's common stock.
When was the stock repurchase program approved?
The stock repurchase program was approved by the Board of Directors on May 30, 2024.
What is the expiration date of the stock repurchase program?
The stock repurchase program is authorized to continue through June 6, 2025.
What is the purpose of the stock repurchase program?
The program reflects the Board's confidence in the value of the company's common stock and its commitment to enhancing shareholder value.
What type of stock is authorized for repurchase?
The program authorizes the repurchase of the company's common stock.
Filing Stats: 433 words · 2 min read · ~1 pages · Grade level 11.4 · Accepted 2024-06-06 16:37:03
Key Financial Figures
- $226,903 — 24 through June 6, 2024, the holders of $226,903 of Original Issue Discount Senior Conve
- $6.00 — n average contractual exercise price of $6.00 per share in exchange for the issuance
Filing Documents
- form8-k.htm (8-K) — 38KB
- 0001493152-24-022945.txt ( ) — 202KB
- sigy-20240606.xsd (EX-101.SCH) — 3KB
- sigy-20240606_lab.xml (EX-101.LAB) — 33KB
- sigy-20240606_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SIGYN THERAPEUTICS, INC. Date: June 6, 2024 By: /s/ James A. Joyce James A. Joyce, Chairman and CEO